Latest Joint Project Manager Transformational Medical Technologies Stories

ALEXANDRIA, Va., Jan. 14, 2013 /PRNewswire/ -- The Tauri Group, LLC is pleased to announce that it has been selected as the prime contractor to provide Advisory & Assistance Services (A&AS) for the Joint Project Manager Transformational Medical Technologies (JPM-TMT). The task order contract has a value of $49 million over the next three years. The Joint Project Manager for Transformational Medical Technologies (JPM-TMT) employs innovative technologies and non-traditional...

JPM-TMT's Strategy in Accordance with Original RFP FORT BELVOIR, Va., Oct. 2, 2012 /PRNewswire-USNewswire/ -- The Department of Defense's (DoD) Joint Program Executive Office for Chemical and Biological Defense, Joint Project Manager Transformational Medical Technologies (JPM-TMT), completed a comprehensive evaluation of its Ebola medical countermeasure (MCM) candidate development efforts and decided that the Hemorrhagic Fever Virus (HFV) program will continue with only one of...

Sarepta Therapeutics, Inc. Will Investigate feasibility of Delivery via Intramuscular Route FORT BELVOIR, Va., Sept. 6, 2012 /PRNewswire-USNewswire/ -- A contract to evaluate an alternative method for delivering a medical countermeasure (MCM) was awarded to Sarepta Therapeutics by the Joint Project Manager Transformational Medical Technologies (JPM-TMT). A component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), JPM-TMT has made significant...

Treatment with JPM-TMTFunded AVI-7288 Shows Significant Survival Rates Even When Administered up to Four Days Post Infection FORT BELVOIR, Va., Aug. 2, 2012 /PRNewswire-USNewswire/ -- A new study testing a drug candidate to treat Marburg virus demonstrated significant survival rates up to four days after exposure to the disease. Referred to as AVI-7288, the drug is a post-exposure prophylactic targeting the Marburg virus which may cause hemorrhagic fever, a severe,...

MediVector, Inc.'s Favipiravir (T-705) targets multiple influenza virus strains FORT BELVOIR, Va., March 15, 2012 /PRNewswire-USNewswire/ -- The Department of Defense's (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract...